- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00540150
Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy
October 4, 2007 updated by: Johann Wolfgang Goethe University Hospital
Compatibility and Immunogenicity of a Short Specific Immunotherapy (SIT) in Contrast to Classic Specific Immunotherapy in a Randomized Study Depending on Mite-Depot Supplement in Children and Adolescents With Allergic Bronchial Asthma.
We wanted to examine the immunogenicity and safety of a shortened specific immunotherapy in contrast to the standard specific immunotherapy.
Therefore, we challenged 12 patients for 14 weeks with the standard specific scheme and 22 patients for 6 weeks with the shortened scheme.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
see above
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hessen
-
Frankfurt, Hessen, Germany, 60590
- Goethe University, Department of Pulmonology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- informed consent of patient and/or parents
- age >6 and <18 years
- bronchial asthma I° or II°
- allergy on house dust-mite
Exclusion Criteria:
- age <6 and >18 years
- vital capacity <80% or FEV1 <70%
- pregnancy
- inhalative or systemic steroid use
- bronchial asthma III° or IV°
- heavy exacerbation during the last 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 1
Standard specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
|
We treat each patient with mite-allergen following the two different protocols.
Other Names:
|
Active Comparator: 2
Shortened specific immunotherapy: Novo-Helisen Depot, Allergopharma Inc., Reinbek, Germany
|
We treat each patient with mite-allergen following the two different protocols.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of the shortened specific immunotherapy.
Time Frame: may 2004 - march 2005
|
may 2004 - march 2005
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Exhaled nitric oxid (eNO) and immunogenicity (IgE, specific IgE, specific IgG) in both groups.
Time Frame: may 2004 - march 2005
|
may 2004 - march 2005
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Stefan Zielen, M.D., Ph.D., Goethe University, Department of Pulmonology
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hansen I, Hormann K, Stuck BA, Schneider-Gene S, Mosges R, Klimek L. [Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)]. Laryngorhinootologie. 2003 Aug;82(8):558-63. doi: 10.1055/s-2003-41234. German.
- Tabar AI, Echechipia S, Garcia BE, Olaguibel JM, Lizaso MT, Gomez B, Aldunate MT, Martin S, Marcotegui F. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005 Jul;116(1):109-18. doi: 10.1016/j.jaci.2005.05.005.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Study Completion (Actual)
March 1, 2005
Study Registration Dates
First Submitted
October 2, 2007
First Submitted That Met QC Criteria
October 4, 2007
First Posted (Estimate)
October 5, 2007
Study Record Updates
Last Update Posted (Estimate)
October 5, 2007
Last Update Submitted That Met QC Criteria
October 4, 2007
Last Verified
September 1, 2007
More Information
Terms related to this study
Other Study ID Numbers
- 97/04/FFM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunotherapy
-
Ajou University School of MedicineCompletedImmunotherapyKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Centre Georges Francois LeclercAstraZenecaActive, not recruiting
-
Power Life Sciences Inc.Not yet recruitingCancer | Immunotherapy
-
Xuanwu Hospital, BeijingRecruitingImmunotherapy | ADRChina
-
Rutgers, The State University of New JerseyPfizer; American Cancer Society, Inc.CompletedImmunotherapy | Clinical TrialsUnited States
-
Peking University First HospitalYiZhou International Cancer HospitalUnknownImmunotherapy | Proton Therapy
-
Nanfang Hospital, Southern Medical UniversityRecruitingImmunotherapy | Biomarker | HyperprogressionChina
-
Peking University First HospitalNot yet recruitingImmunotherapy | SBRT | Bulky Tumor
Clinical Trials on specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)
-
Allergopharma GmbH & Co. KGCompletedHouse Dust Mite AllergyGermany